The company said its Board approved the appointment of Inderpal S. Bhandari as a director on January 18, 2024, effective the same day. His term runs until the 2024 Annual Meeting of Stockholders.

1. 01

   The company said its Board approved the appointment of Inderpal S. Bhandari as a director on January 18, 2024, effective the same day. His term runs until the 2024 Annual Meeting of Stockholders.

2. 02

   The company said Bhandari was appointed to the Innovation and Technology Committee. It said there are no arrangements or understandings between him and any other persons regarding his selection, and that he has no direct or indirect material interest in any transaction required to be reported under Item 404(a).

3. 03

   The company said Bhandari served as Global Chief Data Officer at IBM from December 2015 to July 2023, where he led the company's global data strategy. It said he had spent more than 20 years in the healthcare industry before joining IBM.

4. 04

   The company said Bhandari received an initial grant of deferred stock units (DSUs) valued at $40,000, a pro-rated annual retainer of $26,775.96, and a pro-rated annual deferred incentive compensation grant of DSUs valued at $46,857.92 in connection with his appointment.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.